Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Medical and Pediatric Oncology|January 1, 1997
Case report: congenital retroperitoneal fibrosarcomaC M Hamm, A Pyesmany, L Resch
Cancer Chemotherapy and Pharmacology|January 1, 1979
An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhoodW Krivit, R Chilcote, A Pyesmany, et al.
Cancer Treatment Reports|November 1, 1981
Comparison of the therapeutic response of patients with childhood acute lymphoblastic leukemia in relapse to vindesine versus vincristine in combination with prednisone and L-asparaginase: a phase III trialJ Anderson, W Krivit, R Chilcote, et al.
The American Journal of Pediatric Hematology/Oncology|January 1, 1981
Comparison of vincristine utilized simultaneously or 24 hours before cyclophosphamide in maintenance regimen of acute lymphoblastic leukemia of children: a report of Childrens Cancer Study GroupW Krivit, J Anderson, R Chilcote, et al.
The American Journal of Pediatric Hematology/Oncology|January 1, 1980
A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study GroupW Krivit, J Anderson, R Chilcote, et al.
Medical and Pediatric Oncology|January 1, 1984
Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study GroupN Movassaghi, G Higgins, A Pyesmany, et al.
Cancer|January 15, 1981
Nasopharyngeal carcinoma--a retrospective review of patients less than thirty years of age: a report of Children's Cancer Study GroupR D Jenkin, J R Anderson, B Jereb, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|January 1, 1994
A multicentre randomized study of single-unit dose package of EMLA patch vs EMLA 5% cream for venepuncture in childrenP C Chang, G V Goresky, G O'Connor, et al.
Journal of Pediatric Hematology/Oncology|August 13, 1999
Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapyM J Coppes, R Yanofsky, S Pritchard, et al.
Pageof 1